Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis.
Adenocarcinoma
/ drug therapy
Aged
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Drug-Related Side Effects and Adverse Reactions
/ classification
Female
Fluorouracil
/ adverse effects
Humans
Irinotecan
/ adverse effects
Kaplan-Meier Estimate
Leucovorin
/ adverse effects
Male
Middle Aged
Neoadjuvant Therapy
/ adverse effects
Oxaliplatin
/ adverse effects
Pancreatic Neoplasms
/ drug therapy
Progression-Free Survival
Treatment Outcome
Journal
Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089
Informations de publication
Date de publication:
01 08 2019
01 08 2019
Historique:
received:
19
12
2018
revised:
19
12
2018
accepted:
22
04
2019
pubmed:
16
5
2019
medline:
10
6
2020
entrez:
16
5
2019
Statut:
ppublish
Résumé
FOLFIRINOX is a standard treatment for metastatic pancreatic cancer patients. The effectiveness of neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer (BRPC) remains debated. We performed a systematic review and patient-level meta-analysis on neoadjuvant FOLFIRINOX in patients with BRPC. Studies with BRPC patients who received FOLFIRINOX as first-line neoadjuvant treatment were included. The primary endpoint was overall survival (OS), and secondary endpoints were progression-free survival, resection rate, R0 resection rate, and grade III-IV adverse events. Patient-level survival outcomes were obtained from authors of the included studies and analyzed using the Kaplan-Meier method. We included 24 studies (8 prospective, 16 retrospective), comprising 313 (38.1%) BRPC patients treated with FOLFIRINOX. Most studies (n = 20) presented intention-to-treat results. The median number of administered neoadjuvant FOLFIRINOX cycles ranged from 4 to 9. The resection rate was 67.8% (95% confidence interval [CI] = 60.1% to 74.6%), and the R0-resection rate was 83.9% (95% CI = 76.8% to 89.1%). The median OS varied from 11.0 to 34.2 months across studies. Patient-level survival data were obtained for 20 studies representing 283 BRPC patients. The patient-level median OS was 22.2 months (95% CI = 18.8 to 25.6 months), and patient-level median progression-free survival was 18.0 months (95% CI = 14.5 to 21.5 months). Pooled event rates for grade III-IV adverse events were highest for neutropenia (17.5 per 100 patients, 95% CI = 10.3% to 28.3%), diarrhea (11.1 per 100 patients, 95% CI = 8.6 to 14.3), and fatigue (10.8 per 100 patients, 95% CI = 8.1 to 14.2). No deaths were attributed to FOLFIRINOX. This patient-level meta-analysis of BRPC patients treated with neoadjuvant FOLFIRINOX showed a favorable median OS, resection rate, and R0-resection rate. These results need to be assessed in a randomized trial.
Sections du résumé
BACKGROUND
FOLFIRINOX is a standard treatment for metastatic pancreatic cancer patients. The effectiveness of neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer (BRPC) remains debated.
METHODS
We performed a systematic review and patient-level meta-analysis on neoadjuvant FOLFIRINOX in patients with BRPC. Studies with BRPC patients who received FOLFIRINOX as first-line neoadjuvant treatment were included. The primary endpoint was overall survival (OS), and secondary endpoints were progression-free survival, resection rate, R0 resection rate, and grade III-IV adverse events. Patient-level survival outcomes were obtained from authors of the included studies and analyzed using the Kaplan-Meier method.
RESULTS
We included 24 studies (8 prospective, 16 retrospective), comprising 313 (38.1%) BRPC patients treated with FOLFIRINOX. Most studies (n = 20) presented intention-to-treat results. The median number of administered neoadjuvant FOLFIRINOX cycles ranged from 4 to 9. The resection rate was 67.8% (95% confidence interval [CI] = 60.1% to 74.6%), and the R0-resection rate was 83.9% (95% CI = 76.8% to 89.1%). The median OS varied from 11.0 to 34.2 months across studies. Patient-level survival data were obtained for 20 studies representing 283 BRPC patients. The patient-level median OS was 22.2 months (95% CI = 18.8 to 25.6 months), and patient-level median progression-free survival was 18.0 months (95% CI = 14.5 to 21.5 months). Pooled event rates for grade III-IV adverse events were highest for neutropenia (17.5 per 100 patients, 95% CI = 10.3% to 28.3%), diarrhea (11.1 per 100 patients, 95% CI = 8.6 to 14.3), and fatigue (10.8 per 100 patients, 95% CI = 8.1 to 14.2). No deaths were attributed to FOLFIRINOX.
CONCLUSIONS
This patient-level meta-analysis of BRPC patients treated with neoadjuvant FOLFIRINOX showed a favorable median OS, resection rate, and R0-resection rate. These results need to be assessed in a randomized trial.
Identifiants
pubmed: 31086963
pii: 5488951
doi: 10.1093/jnci/djz073
pmc: PMC6695305
doi:
Substances chimiques
folfirinox
0
Oxaliplatin
04ZR38536J
Irinotecan
7673326042
Leucovorin
Q573I9DVLP
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
782-794Subventions
Organisme : NCI NIH HHS
ID : K12 CA226330
Pays : United States
Organisme : Pancreatic Cancer UK
ID : RIF2015_A06_JAMIESON
Pays : United Kingdom
Organisme : NIGMS NIH HHS
ID : U54 GM104942
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Ann Surg. 2019 Apr;269(4):733-740
pubmed: 29227344
Oncology. 2015;89(1):37-46
pubmed: 25766660
Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2):296-303
pubmed: 27475674
J Natl Compr Canc Netw. 2017 Aug;15(8):1028-1061
pubmed: 28784865
Ann Surg Oncol. 2017 Sep;24(9):2734-2743
pubmed: 28560601
Cancer Chemother Pharmacol. 2016 Oct;78(4):719-26
pubmed: 27501851
PLoS Med. 2010 Apr 20;7(4):e1000267
pubmed: 20422030
Br J Surg. 2018 Jul;105(8):946-958
pubmed: 29708592
Ann Surg Oncol. 2009 Jul;16(7):1727-33
pubmed: 19396496
Eur J Surg Oncol. 2017 Sep;43(9):1711-1717
pubmed: 28688722
J Clin Oncol. 2008 Jul 20;26(21):3487-95
pubmed: 18640929
N Engl J Med. 2018 Dec 20;379(25):2395-2406
pubmed: 30575490
Eur Radiol. 2017 Aug;27(8):3408-3435
pubmed: 28093626
JAMA Surg. 2016 Aug 17;151(8):e161137
pubmed: 27275632
J Gastrointest Oncol. 2013 Dec;4(4):370-3
pubmed: 24294508
Ann Surg Oncol. 2006 Aug;13(8):1035-46
pubmed: 16865597
Ann Surg Oncol. 2015 Apr;22(4):1153-9
pubmed: 25358667
Pancreatology. 2015 Nov-Dec;15(6):667-73
pubmed: 26412296
Chin J Cancer Res. 2015 Aug;27(4):376-91
pubmed: 26361407
Ann Surg. 2014 Jul;260(1):142-8
pubmed: 24901360
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
Oncotarget. 2017 Jul 11;8(28):46337-46347
pubmed: 28564637
Ann Surg Oncol. 2013 Aug;20(8):2787-95
pubmed: 23435609
Ann Surg. 2014 Aug;260(2):372-7
pubmed: 24374509
BMC Cancer. 2017 Jul 27;17(1):505
pubmed: 28750659
J Gastrointest Surg. 2017 Sep;21(9):1420-1427
pubmed: 28597320
Lancet. 2017 Mar 11;389(10073):1011-1024
pubmed: 28129987
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
Medicine (Baltimore). 2014 Dec;93(27):e198
pubmed: 25501072
BMC Surg. 2017 Aug 25;17(1):94
pubmed: 28841916
J Natl Cancer Inst. 2014 Mar;106(3):dju011
pubmed: 24563516
Eur J Radiol. 2013 Apr;82(4):589-93
pubmed: 23287712
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
JOP. 2012 Sep 10;13(5):497-501
pubmed: 22964956
Oncologist. 2014 Mar;19(3):266-74
pubmed: 24569947
J Surg Oncol. 2016 Oct;114(5):587-596
pubmed: 27444658
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Clin Colorectal Cancer. 2014 Dec;13(4):232-8
pubmed: 25442814
J Gastrointest Oncol. 2017 Aug;8(4):683-695
pubmed: 28890819
J Clin Oncol. 2008 Jul 20;26(21):3496-502
pubmed: 18640930
J Am Coll Surg. 2012 Jan;214(1):33-45
pubmed: 22055585
Pancreas. 2013 Nov;42(8):1311-5
pubmed: 24152956
Ann Surg. 2015 Jan;261(1):12-7
pubmed: 25599322
Cancer Med. 2017 Jul;6(7):1552-1562
pubmed: 28639410
Acta Oncol. 2013 Aug;52(6):1231-3
pubmed: 23445338
BMC Cancer. 2018 Jul 24;18(1):762
pubmed: 30041614
Lancet Oncol. 2016 Jun;17(6):801-810
pubmed: 27160474
Acta Oncol. 2015 Jul;54(7):979-85
pubmed: 25734581
Br J Cancer. 2016 Mar 29;114(7):737-43
pubmed: 27022826
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1196-205
pubmed: 26271395
J Clin Oncol. 2005 Feb 20;23(6):1228-36
pubmed: 15718320
Ann Surg. 2018 Aug;268(2):215-222
pubmed: 29462005
Am J Clin Oncol. 2016 Feb;39(1):1-7
pubmed: 26132367
J Surg Oncol. 2013 Sep;108(4):236-41
pubmed: 23955427
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120